Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302
Open Access
- 11 May 2022
- journal article
- research article
- Published by Elsevier in European Journal of Cancer
- Vol. 170, 296-304
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate CancerNew England Journal of Medicine, 2014
- Use of Statins and the Risk of Death in Patients With Prostate CancerJournal of Clinical Oncology, 2014
- Metformin Use and All-Cause and Prostate Cancer–Specific Mortality Among Men With DiabetesJournal of Clinical Oncology, 2013
- Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyNew England Journal of Medicine, 2013
- Lower Risk of Cancer in Patients on Metformin in Comparison With Those on Sulfonylurea DerivativesDiabetes Care, 2011
- Comparative effects of high and low-dose simvastatin on prostate epithelial cells: The role of LDLEuropean Journal of Pharmacology, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Metformin use and prostate cancer in Caucasian men: results from a population-based case–control studyCancer Causes & Control, 2009
- Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control StudyAmerican Journal of Epidemiology, 2008
- Metformin and reduced risk of cancer in diabetic patientsBMJ, 2005